Replies to post #139801 on Biotech Values

[DewDiligence]

WPI/AGN—I think the 0.03% formulation still counts for majority of sales and from the link you've posted it looks like WPI is challenging both formulations patents but my guess is they will not bother challenging the older patents and will attack the later patent protecting the 0.01% (U.S. 7,851,504).

That’s right—the 0.01% formulation of Lumigan has not gained much traction yet, but it should supersede the 0.03% formulation as the SoC in due course because it’s simply a better product. Your conjecture about WPI’s IP strategy thus makes perfect sense.